10-氮杂双环[4.3.1]癸烷盐酸盐 | 282-57-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 中文名称: 10-氮杂双环[4.3.1]癸烷盐酸盐
• 英文名称: 10-aza-bicyclo[4.3.1]decane
• 英文别名: 10-Aza-bicyclo[4.3.1]decan；10-Azabicyclo[4.3.1]decane
• CAS: 282-57-5
• 化学式: C₉H₁₇N
• mdl: MFCD08691647
• 分子量: 139.241
• InChiKey: QWDHUFQYOCRGFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  10-氮杂双环[4.3.1]癸烷盐酸盐 在 氯仿 、 硫酸 、 三氯乙醛 作用下， 生成 10-甲酰基-10-氮杂-二环[4.3.1]癸烷
  参考文献：
  名称：

  Unsaturated Amines. XII. Steric Requirements of Mercuric Acetate Oxidation of Tertiary Amines¹

  摘要：

  DOI：

  10.1021/ja01535a031
• 作为产物：
  描述：

  10-methyl-10-azabicyclo[4.3.1]decan-8-one 在 氢氧化钾 、 mercury(II) diacetate 、 一水合肼 、 溶剂黄146 、 三乙二醇 作用下， 生成 10-氮杂双环[4.3.1]癸烷盐酸盐
  参考文献：
  名称：

  Unsaturated Amines. XII. Steric Requirements of Mercuric Acetate Oxidation of Tertiary Amines¹

  摘要：

  DOI：

  10.1021/ja01535a031

文献信息

• [EN] ISOXAZOLE CARBOXAMIDE COMPOUNDS<br/>[FR] COMPOSÉS CARBOXAMIDES ISOXAZOLES
  申请人：EPIZYME INC

  公开号：WO2016040498A1

  公开（公告）日：2016-03-17

  The present disclosure provides substituted isoxazole carboxamide compounds having Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

  本公开提供具有式（I）的替代异噁唑羧酰胺化合物及其药用可接受的盐和溶剂化合物，其中R1、R2、A、X和Z如规范中所述。本公开还涉及使用式I的化合物治疗对SMYD蛋白的阻断具有响应的疾病，如SMYD3或SMYD2。本公开的化合物特别适用于治疗癌症。
• SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF
  申请人：Shionogi & Co., Ltd.

  公开号：US20140187535A1

  公开（公告）日：2014-07-03

  The disclosure relates to Substituted Benzimidazole-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable salts or solvates thereof, e.g., a pharmaceutically acceptable salt or solvate, wherein R 1 , R 2 , R 3 , Q a , W, U, A, B, Z, a, and the dashed lines are as defined herein, compositions comprising an effective amount of a Substituted Benzimidazole-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted Benzimidazole-Type Piperidine Compound.

  该披露涉及式(I)的取代苯并咪唑基哌啶化合物及其药学上可接受的盐或溶剂，例如药学上可接受的盐或溶剂，其中R1、R2、R3、Qa、W、U、A、B、Z、a和虚线如本文所定义，包括有效量的取代苯并咪唑基哌啶化合物的组合物，以及治疗或预防疾病的方法，例如疼痛，包括向需要的动物施用有效量的取代苯并咪唑基哌啶化合物。
• [EN] AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE PIPÉRIDINE DE TYPE QUINOXALINE SUBSTITUÉE PAR UNE AZÉTIDINE ET LEURS UTILISATIONS
  申请人：PURDUE PHARMA LP

  公开号：WO2013080036A1

  公开（公告）日：2013-06-06

  The disclosure relates to Azetidine-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein the R1, R2, R3, Q, Y1, Z, A, B, a, and b are as defined herein, compositions comprising an effective amount of an Azetidine-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Azetidine-Substituted Quinoxaline-Type Piperidine Compound.

  该披露涉及公式(I)的氮杂环丙烷取代喹喔啉型哌啶化合物及其药用可接受的衍生物，其中R1、R2、R3、Q、Y1、Z、A、B、a和b如本文所定义，包含有效量氮杂环丙烷取代喹喔啉型哌啶化合物的组合物，以及治疗或预防疾病（如疼痛）的方法，包括向需要的动物施用有效量氮杂环丙烷取代喹喔啉型哌啶化合物。
• [EN] SUBSTITUTED PIPERIDINE COMPOUNDS<br/>[FR] COMPOSÉS PIPÉRIDINES SUBSTITUÉS
  申请人：EPIZYME INC

  公开号：WO2016040515A1

  公开（公告）日：2016-03-17

  The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

  本公开提供具有式（I）的取代哌啶化合物，以及其药学上可接受的盐和溶剂化合物，其中R1、B、X和Z如规范中所述。本公开还涉及使用式I的化合物治疗对SMYD蛋白质的阻断具有响应的疾病，如SMYD3或SMYD2。本公开的化合物特别适用于治疗癌症。
• OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF
  申请人：Shionogi & Co., Ltd.

  公开号：US20140187544A1

  公开（公告）日：2014-07-03

  The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 20 , R 21 , Q, Y 1 , Z, A, B, and a are as defined herein; compositions comprising an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound.

  本公开涉及氧肟取代的喹喔啉型哌啶化合物，例如公式（I）中的化合物及其药用可接受的盐和溶剂化合物，其中R1、R2、R3、R4、R20、R21、Q、Y1、Z、A、B和a如本文所定义；包含有效量氧肟取代的喹喔啉型哌啶化合物的组合物，以及治疗或预防疾病的方法，例如疼痛，包括向需要治疗的动物施用有效量的氧肟取代的喹喔啉型哌啶化合物。